<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Sneddon’s syndrome is a rare but severe progressive chronic disease, characterized by multiple discoloration skin patches called Livedo racemosa and recurrent cerebrovascular events. It mainly affects women aged around 40. Considering the two main forms, antiphospholipid (APS) positive and negative, the available treatments are directed at either one of them. The idiopathic form (APS negative) is associated with a more severe prognosis as chronic oral anticoagulant therapy (COA) is more difficult to manage. One therapeutic perspective in controlling disease progression in these patients is by understanding the protein Z deficiency in these patients as a deciding factor in the success of the COA therapy.</p>
</abstract>

Sneddon’s syndrome is a rare but severe progressive chronic disease, characterized by multiple discoloration skin patches called Livedo racemosa and recurrent cerebrovascular events. It mainly affects women aged around 40. Considering the two main forms, antiphospholipid (APS) positive and negative, the available treatments are directed at either one of them. The idiopathic form (APS negative) is associated with a more severe prognosis as chronic oral anticoagulant therapy (COA) is more difficult to manage. One therapeutic perspective in controlling disease progression in these patients is by understanding the protein Z deficiency in these patients as a deciding factor in the success of the COA therapy.

Therapeutic Perspectives in Sneddon’s Syndrome

“Grigore T. Popa” University of Medicine and Pharmacy

Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Therapeutic Perspectives in Sneddon\u2019s Syndrome"}

Sneddon’s syndrome is a rare but severe progressive chronic disease, characterized by multiple discoloration skin patches called Livedo racemosa and recurrent...

Therapeutic Perspectives in Sneddon’s Syndrome

Publié en ligne: 15 nov. 2021

Pages: 73 - 80

DOI: https://doi.org/10.2478/inmed-2021-0184

Mots clés
Sneddon’s syndrome, chronic oral anticoagulation, protein Z deficiency

© 2021 Oana-Petronela Oancea et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Therapeutic Perspectives in Sneddon’s Syndrome

Publié en ligne: 15 nov. 2021

Pages: 73 - 80

DOI: https://doi.org/10.2478/inmed-2021-0184

Mots clésSneddon’s syndrome, chronic oral anticoagulation, protein Z deficiency

© 2021 Oana-Petronela Oancea et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
Sneddon’s syndrome, chronic oral anticoagulation, protein Z deficiency